

BROADCAST SCRIPT #1: JOY'S STORY

INTRO:

TOLD SHE HAD JUST SIX MONTHS TO LIVE FOLLOWING A STAGE 4 LUNG CANCER DIAGNOSIS, JOY AMUNDSON WAS RUNNING OUT OF OPTIONS.

FOR NEARLY 12 YEARS, THE 53-YEAR-OLD PEORIA, ILLINOIS NATIVE HAD ENDURED CANCER SPREADING THROUGHOUT HER BODY AND SIX DIFFERENT TREATMENT APPROACHES, INCLUDING SURGERY, CHEMOTHERAPY AND IMMUNOTHERAPY.

TAKE VO:

THEN... A BIOMARKER IN AMUNDSON'S CANCER HELPED UNLOCK AN ENTIRELY NEW POSSIBILITY.

A TEAM AT OSF HEALTHCARE CANCER INSTITUTE IN PEORIA FOUND A POTENTIAL TREATMENT THAT HAD NEVER BEEN APPROVED FOR AMUNDSON'S SPECIFIC DISEASE. OSF SECURED THAT ACCESS IN JUST TWO DAYS.

LESS THAN SIX WEEKS AFTER AMUNDSON BEGAN TREATMENT, THE TUMOR IN HER LIVER HAD SHRUNK BY MORE THAN HALF ITS SIZE. THE CHANGE WASN'T CONFINED TO AN IMAGE ON A SCREEN.

AMUNDSON COULD FEEL IT.

TAKE SOT | JOY AMUNDSON | BATTLING STAGE 4 LUNG CANCER:

"My symptoms have improved dramatically. I don't have nearly as much pain. I was having trouble eating before and a lot of abdominal pain with that, which is now gone. That's dramatically improved my quality of life."

VO TAG:

TREATMENT WILL CONTINUE EVERY OTHER WEEK AS LONG AS HER CANCER CONTINUES RESPONDING AND SHE IS ABLE TO TOLERATE THE MEDICATION. FOR AMUNDSON... HOWEVER... THE SCIENCE ULTIMATELY COMES DOWN TO SOMETHING MUCH SIMPLER.

TIME.

LEARN MORE ABOUT OSF HEALTHCARE CANCER INSTITUTE AT [OSFHEALTHCARE.ORG/CANCER](https://osfhealthcare.org/cancer).

SCRIPT #2: REVOLUTIONARY CANCER TREATMENT

INTRO:

TOLD SHE HAD JUST SIX MONTHS TO LIVE FOLLOWING A STAGE 4 LUNG CANCER DIAGNOSIS... JOY AMUNDSON WAS RUNNING OUT OF OPTIONS.

FOR NEARLY 12 YEARS... THE 53-YEAR-OLD PEORIA... ILLINOIS NATIVE HAD ENDURED CANCER SPREADING THROUGHOUT HER BODY AND SIX DIFFERENT TREATMENT APPROACHES... INCLUDING SURGERY... CHEMOTHERAPY AND IMMUNOTHERAPY.

THEN... A BIOMARKER IN AMUNDSON'S CANCER HELPED UNLOCK AN ENTIRELY NEW POSSIBILITY.

TAKE VO:

WITH AMUNDSON RUNNING OUT OF CONVENTIONAL TREATMENT OPTIONS... DR. JUN ZHANG... THE VICE PRESIDENT OF ONCOLOGY RESEARCH AT OSF HEALTHCARE CANCER INSTITUTE... AND HIS TEAM BEGAN LOOKING DEEPER INTO THE BIOLOGY OF HER CANCER FOR ANOTHER POSSIBILITY.

THE FINDING GAVE DR. ZHANG A POTENTIAL TARGET – AND A POTENTIAL TREATMENT.

DR. ZHANG AND THE CLINICAL RESEARCH TEAM AT THE OSF CANCER INSTITUTE BREAKTHROUGH TREATMENT CENTER SUBMITTED A REQUEST THROUGH THE FDA'S EXPANDED ACCESS PROGRAM... WHICH CAN ALLOW SOMEONE WITH A SERIOUS OR IMMEDIATELY LIFE-THREATENING DISEASE TO RECEIVE AN INVESTIGATIONAL THERAPY OUTSIDE OF A CLINICAL TRIAL WHEN CERTAIN CRITERIA ARE MET.

THEY RECEIVED APPROVAL IN TWO DAYS.

TAKE SOT | DR. JUN ZHANG | VICE PRESIDENT OF ONCOLOGY RESEARCH | OSF HEALTHCARE CANCER INSTITUTE

"The fourth dose we did in an outpatient setting. And guess what? She's able to tolerate the treatment so well... and we just got a scan done [at less than six weeks]... and when we opened the scans... everyone was shocked and extremely excited. The tumor in the liver that was about 10 centimeters... has now shrunk to between four to five centimeters – over a 50% reduction."

VO TAG:

FOR DR. ZHANG... AMUNDSON'S CASE ILLUSTRATES HOW RAPIDLY CANCER TREATMENT IS EVOLVING.

NEW THERAPIES AND AN EXPANDING UNDERSTANDING OF TUMOR BIOMARKERS ARE INCREASINGLY GIVING CANCER TEAMS OPPORTUNITIES TO LOOK BEYOND WHERE A CANCER ORIGINATED AND INVESTIGATE THE SPECIFIC CIRCUMSTANCES THAT MAY MAKE AN INDIVIDUAL TUMOR VULNERABLE TO TREATMENT.

LEARN MORE ABOUT THE EXCITING WORK OF THE OSF BREAKTHROUGH TREATMENT CENTER AT [BREAKTHROUGH.OSFHEALTHCARE.ORG](https://breakthrough.osfhealthcare.org).